retatrutide approved by fda Weight Loss Results:Trial Data and Status Retatrutide, an experimental weight-loss drug,

Protocol 2: significant weight loss (20-25% body weight) Goal: Substantial weight reduction for health improvement Tirzepatide approach: Full escalation to 10-15 mg Expect to reach target dose by week 17-21 Weight loss at 15 mg: approximately 22.5% at 72 weeks Plateau typically occurs around weeks 60-72 Retatrutide approach: Full escalation to 8-12 mg Expect to reach target dose by week 13-17 Weight loss at 12 mg: 24.2% at 48 weeks, 28.7% at 68 weeks No plateau observed in trial data at 48 or 68 weeks For significant weight loss goals, retatrutide reaches 20%+ body weight reduction faster and ultimately achieves a higher ceiling

Do any switch under a clinician's supervision

Ive worked for large, enterprise-level weight-loss companies running million-dollar ad campaigns, as well as for smaller, fast-moving startups that popped up during the FDA shortages

Licensed by MHRA in the UK : Pending registration Estimated Mid 2026 Licensed by FDA in the US : Pending registration Estimated Mid 2026 Licensed by EMA in the EU : Pending registration- Estimated Mid 2026 Frequently Asked Questions What is the dose titration or escalation for Orforglipron 3 mg, 12 mg, and 36 mg Tablets

What youll learn: Both Jardiance and Ozempic are medications approved for the treatment of type 2 diabetes that can be prescribed off-label for weight loss